Pro-angiogenic therapeutics for preeclampsia.

Area of Science:

• Obstetrics and Gynecology
• Cardiovascular Research
• Maternal-Fetal Medicine

Background:

• Preeclampsia is a pregnancy-induced hypertensive disorder linked to abnormal placentation and angiogenic imbalance.
• Elevated levels of soluble fms-like tyrosine kinase-1 (sFlt-1) in maternal circulation disrupt vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) bioavailability.
• Current treatments for preeclampsia offer limited control over the syndrome's progression.

Purpose of the Study:

• To review the role of angiogenic imbalance in preeclampsia pathogenesis.
• To discuss therapeutic strategies targeting angiogenic factors in preeclampsia models.
• To evaluate the potential of placental growth factor (PlGF) as a safe therapeutic option.

Main Methods:

• Review of existing literature on preeclampsia, sFlt-1, VEGF, and PlGF.
• Analysis of studies investigating the administration of sFlt-1 and its effects.
• Examination of preclinical studies on VEGF and PlGF as therapeutic interventions.

Main Results:

• Administration of sFlt-1 induces a preeclamptic phenotype in experimental models.
• Elevated plasma sFlt-1 levels are associated with preeclampsia progression.
• Treatment with VEGF or PlGF has shown efficacy in attenuating hypertension and proteinuria in preeclampsia models.

Conclusions:

• Angiogenic imbalance, particularly driven by sFlt-1, is central to preeclampsia.
• Placental growth factor (PlGF) represents a potentially safer therapeutic avenue compared to VEGF due to observed toxicity risks with VEGF.
• Restoring angiogenic balance is a key therapeutic goal for managing preeclampsia.